American Journal of Health-System Pharmacy最新文献

{"title":"Commission on Goals dives into evolving healthcare landscape.","authors":"-Kate Traynor","doi":"10.1093/ajhp/zxaf108","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf108","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In memory of Tara N. Kelley, 1979-2025.","authors":"Kate Traynor","doi":"10.1093/ajhp/zxaf109","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf109","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actions of the ASHP Board of Directors - Meeting of January 23-24, 2025.","authors":"","doi":"10.1093/ajhp/zxaf040","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf040","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of pharmacy student involvement in collecting the best possible medication histories in hospital settings: A scoping review.","authors":"Ivana Tadic, Julia Alexandra Schintler, Anita Elaine Weidmann","doi":"10.1093/ajhp/zxaf101","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf101","url":null,"abstract":"<p><strong>Disclaimer: </strong>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p><p><strong>Purpose: </strong>To assess the current extent of pharmacy students' involvement in collecting best possible medication histories (BPMHs) in different hospital settings, as well as the accuracy and financial implications of the collected BPMHs.</p><p><strong>Summary: </strong>A scoping review methodology was conducted following best-practice Cochrane guidance with findings reported using the PRISMA Extension for Scoping Reviews. An appropriate search string was developed followed by a search across databases: PubMed, PubPharm, LIVIVO, PubMed Central, and Web of Science. All selected studies were published between 2000 and 2023 and met the predetermined inclusion criteria. After removing duplicates and independent screening of titles, abstracts, and full texts, 20 papers were retained. The highest number of original research papers originated from the US (n = 13, 72%). In these papers, the number of patients whose medication histories were collected ranged from 40 to 4,070 (mean, 504.6) and the number of pharmacy students who collected BPMHs ranged from 2 to 71 (mean, 17.8). Students obtained BPMHs alone or in a team with healthcare professionals (HCPs). Several papers described additional training for students. The information sources used were face-to-face patient interviews, data from community pharmacies, and interviews with HCPs and caregivers. Studies demonstrated that students can accurately collect BPMHs, identify unintentional discrepancies, and suggest healthcare interventions. Two studies identified notable cost savings from clinical interventions by pharmacy students.</p><p><strong>Conclusion: </strong>Pharmacy students can accurately collect BPMHs. The results of this scoping review can inform the development of pharmacy curricula to enhance students' competencies and student pharmacy services that can contribute to patients' safety.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive pharmacy-based investigational drug service: A 40-year update.","authors":"Helen Karpov, Kevin Zinchuk, Jon Silverman","doi":"10.1093/ajhp/zxaf104","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf104","url":null,"abstract":"<p><strong>Disclaimer: </strong>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p><p><strong>Purpose: </strong>A review of services and developments over a 40-year period will be included, reflecting significant advances in the field of pharmacy-based investigational drug services (IDS) at an 836-bed teaching hospital in Boston, MA.</p><p><strong>Summary: </strong>The institution's IDS, established in 1980, has seen significant changes due to advancements in technology and regulatory requirements. Reliance on paper-based systems has shifted to utilization of electronic and automated systems such as the Investigation Drug Service Information System (IDSIS), electronic health records, and electronic temperature monitoring. Key updates have included barcode scanning and the implementation of an automated pharmacy carousel system. Regulatory compliance with new standards has driven changes in hazardous medication handling and compounding procedures while the scope of research has expanded to include complex treatments including gene and cell therapies. The growth in research activities and technological integration has led to an increase in both the volume and capacity of the study protocols managed by IDS.</p><p><strong>Conclusion: </strong>The institution's IDS pharmacy has evolved significantly from its inception, reflecting broader trends in research pharmacy. Technological advancements and regulatory requirements have transformed IDS practices, leading to increased efficiency and safety in the management of investigational agents. IDS's capacity to manage a broader range of research studies and its expanded role in research highlight its vital position in advancing clinical trials.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Darbepoetin alfa use in trauma and acute care surgery patients who abstain from blood products: A case series and discussion.","authors":"Madilyn Harris, Jacqueline Bishop, William J Olney, Dina Ali, Alexis Nickols, Sara E Parli","doi":"10.1093/ajhp/zxaf099","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf099","url":null,"abstract":"<p><strong>Disclaimer: </strong>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p><p><strong>Purpose: </strong>Individuals may abstain from blood products due to religious or cultural beliefs. For trauma victims, blood loss is associated with anemia, decreasing oxygen delivery, and alternative treatment methods to blood transfusion are warranted in this population. Literature has investigated the use of epoetin alfa, an albumin-containing erythropoiesis-stimulating agent (ESA), to treat anemia for this indication; however, this may be problematic as albumin is a blood-derived product. Darbepoetin alfa is an albumin-free ESA alternative. This case series describes the use of darbepoetin alfa on anemia and outcomes in patients who abstain from blood products.</p><p><strong>Summary: </strong>Trauma and acute care surgery patients are at risk for development of anemia related to traumatic injury as well as acute blood loss. Blood product transfusion is a common therapeutic intervention; however, patients may abstain from blood product administration. The 9 patients described herein with anemia (hemoglobin concentration of <7 g/dL or hematocrit level of <21%) during a hospital stay abstained from blood products and received darbepoetin alfa. Initial hemoglobin levels ranged from 4.1 to 10.1 g/dL, and patients received darbepoetin from 1 day to up to 17 consecutive days during their hospital stay. One patient experienced a type II non-ST elevation myocardial infarction.</p><p><strong>Conclusion: </strong>The use of darbepoetin alfa appeared to be a therapeutic option to treat anemia in trauma and acute care surgery patients who abstain from blood products. Future studies are needed to compare epoetin alfa and darbepoetin alfa.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gravimetric compounding workflow technology insights for pharmacists and pharmacy technicians.","authors":"Craig Greszler, Nathan E Barnes, Michael J Freudiger, Anthony Giazzon, Neil Hunter, Christopher S Jerry, Jodi Meier, Leigh Ann Miley, Joshua Schmees, Kristine Smith, Jamie Tharp, Matthew Tupps, Angela W Yaniv","doi":"10.1093/ajhp/zxaf102","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf102","url":null,"abstract":"<p><p>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supporting resident well-being: Considerations for residency program directors and pharmacy enterprise leadership.","authors":"Lisa Whittington Goldstone, Peter N Johnson, Deanna Fliehman, Katie Hayes, Stacy Taylor, Elva Angelique Van Devender, Richard Chan","doi":"10.1093/ajhp/zxaf100","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf100","url":null,"abstract":"<p><p>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19.","authors":"Daniel C Malone, Joseph Biskupiak, Diana Brixner, Gary Oderda, Roger Seheult","doi":"10.1093/ajhp/zxae318","DOIUrl":"10.1093/ajhp/zxae318","url":null,"abstract":"<p><strong>Purpose: </strong>COVID-19 patients in intensive care units (ICUs) requiring invasive mechanical ventilation (IMV) have few available treatment options. PANAMO, a multicenter, double-blind, randomized, placebo-controlled phase 3 study of vilobelimab, which blocks the inflammatory process caused by complement component 5a, demonstrated a significant mortality benefit at 28 and 60 days in these patients. A cost-effectiveness analysis was conducted to assess the incremental cost per quality-adjusted life-year (QALY).</p><p><strong>Methods: </strong>A Markov model was used to estimate QALYs and the incremental cost-effectiveness ratio (ICER) of vilobelimab plus standard of care (SOC) versus SOC alone. The model simulated progression from severe COVID-19 to survival or death over a lifetime horizon. Outcomes data (COVID-19 all-cause mortality and renal replacement therapy) were incorporated from the PANAMO trial. COVID-19 mortality estimates were based on Centers for Disease Control and Prevention age-specific survival data. Utility values and hospital costs came from the literature. Vilobelimab cost was obtained from RED BOOK Online.</p><p><strong>Results: </strong>For COVID-19 ICU patients, total costs of care were $103,414 (SOC) and $132,247 (SOC plus vilobelimab), respectively, resulting in an incremental cost of $28,833. SOC provided 6.70 QALYs versus 7.99 QALYs for vilobelimab, an additional 1.29 QALYs. The ICER for vilobelimab plus SOC versus SOC alone was $22,287/QALY. Probabilistic sensitivity analysis demonstrated the robustness of the cost-effectiveness result as vilobelimab plus SOC was favored at a willingness-to-pay threshold of $50,000 in over 81% of iterations.</p><p><strong>Conclusion: </strong>Vilobelimab provides a cost-effective option to treat ICU patients with severe COVID-19 receiving IMV compared to SOC, at well below the commonly accepted $50,000 US willingness-to-pay threshold.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"e438-e446"},"PeriodicalIF":2.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescriptions for progress: How pharmacy education is using AI.","authors":"Jodie Tillman","doi":"10.1093/ajhp/zxaf068","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf068","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":"82 9","pages":"e409-e411"},"PeriodicalIF":2.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}